New combo therapy shows promise for hard-to-treat lung cancer

NCT ID NCT02823990

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested a combination of a cancer vaccine (TG4010) and an immunotherapy drug (nivolumab) in 13 people with advanced non-small cell lung cancer who had already received other treatments. The goal was to see if the combination could shrink tumors or stop them from growing. While the approach aims to boost the immune system to fight cancer, it is not a cure because lung cancer often requires ongoing management.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT NON-SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • UCSF Medical Center-Mount Zion

    San Francisco, California, 94115, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

  • University of California San Diego

    San Diego, California, 92103, United States